Prognostic implication of Ki-67 immunostaining in treating subclinical pleural cancer found at thoracotomy in lung cancer patients

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

“…Immunohistochemistry used to reveal Ki-67 protein was not always performed with the same antibody: clone Mib-1 in the majority of the studies (Costes et al, 1995;Bohm et al, 1996;Fontanini et al, 1996;Bellotti et al, 1997;Ishida et al, 1997;Komaki et al, 1998;Dazzi et al, 1999;Dingemans et al, 1999Dingemans et al, , 2001Santinelli et al, 1999;Cagini et al, 2000;Demarchi et al, 2000;Hommura et al, 2000;Nguyen et al, 2000;Shiba et al, 2000Shiba et al, , 2001van de Vaart et al, 2000;Ferreira et al, 2001;Hayashi et al, 2001;Puglisi et al, 2001Puglisi et al, , 2002Ramnath et al, 2001;Tsoli et al, 2001;Minami et al, 2002;Rigau et al, 2002), antibodies coming from a firm selling several clones but without mention of the clone used (Hayashi et al, 1993;Pence et al, 1993;Kawai et al, 1994;Giaccone et al, 1995;Pujol et al, 1996;Mehdi et al, 1998;Soomro et al, 1998;Carbognani et al, 2002); any mention of the antibodies used (Tungekar et al, 1991;Harpole Jr et al, 1995Giatromanolaki et al, 1996a, b;D'Amico et al, 1999D'Amico et al, , 2000Carvalho et al, 2000;Pelosi et al, 2001)…”

“…The antibodies concentration is also a factor having an influence on the staining result because of the intensity is correlated to the antibody concentration used. This aspect of the immunohistochemistry does not seem important for some authors because they do not specify the antibodies concentration (Tungekar et al, 1991;Hayashi et al, 1993;Costes et al, 1995;Harpole Jr et al, 1995Giatromanolaki et al, 1996a, b;Pujol et al, 1996;D'Amico et al, 1999D'Amico et al, , 2000Dazzi et al, 1999;Santinelli et al, 1999;Nguyen et al, 2000;Shiba et al, 2000Shiba et al, , 2001Pelosi et al, 2001;Carbognani et al, 2002;Minami et al, 2002). Sometimes the immunohistochemical technique was performed without prior reaction for unmasked epitope on fixed tissue.…”

“…In total, 42 studies published between 1991 and 2002 were selected for this systematic review (Tungekar et al, 1991;Hayashi et al, 1993;Pence et al, 1993;Kawai et al, 1994;Costes et al, 1995;Giaccone et al, 1995;Harpole, Jr et al, 1995Bohm et al, 1996;Fontanini et al, 1996;Giatromanolaki et al, 1996a, b;Pujol et al, 1996;Bellotti et al, 1997;Ishida et al, 1997;Komaki et al, 1998;Mehdi et al, 1998;Soomro et al, 1998;D'Amico et al, 1999D'Amico et al, , 2000Dazzi et al, 1999;Dingemans et al, 1999Dingemans et al, , 2001Santinelli et al, 1999;Cagini et al, 2000;Carvalho et al, 2000;Demarchi et al, 2000;Hommura et al, 2000;Nguyen et al, 2000;Shiba et al, 2000Shiba et al, , 2001van de Vaart et al, 2000;Ferreira et al, 2001;Hayashi et al, 2001;Pelosi et al, 2001;Puglisi et al, 2001Puglisi et al, , 2002Ramnath et al, 2001;Tsoli et al, 2001;Carbognani et al, 2002;Minami et al, 2002;Rigau et al, 2002). Five were excluded because an identical patients cohort was used in another selected publication (references excluded/includ...…”

“…Five were excluded because an identical patients cohort was used in another selected publication (references excluded/included: D 'Amico et al, 2000'Amico et al, /1999Giatromanolaki et al, 1996aGiatromanolaki et al, /1996bHarpole Jr. et al, 1995Puglisi et al, 2002Puglisi et al, /2001Shiba et al, 2001Shiba et al, /2000.…”

Management of occult malignant pleural disease firstly detected at thoracotomy for non-small cell lung cancer patients

“…MPD is often discovered at thoracotomy for the NSCLC patients, and the treatment of primary cancer lesion is always controversial (4)(5)(6)(7)(8).…”